Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.

Annie F Fang1, Bharat D Damle, Robert R LaBadie

  • 1Pfizer Inc., New York, New York, USA. annie.f.fang@pfizer.com

Pharmacotherapy
|December 25, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does Dialogue-Based Learning Motivate COVID-19 Preventive Behavior Among Correctional Officers?

Health promotion practice·2026
Same author

Do We Have a Common Understanding of How Vaccine Policy Affects Health Equity? Evaluating Variability in the Advisory Committee on Immunization Practices' Equity Assessment.

Vaccines·2025
Same author

Addressing COVID-19 and Health Literacy Disparities Among Correctional Facility Residents Through Dialogue-Based Education.

Journal of correctional health care : the official journal of the National Commission on Correctional Health Care·2024
Same author

Public Health Response to SARS-CoV-2 in Assisted Living Facilities in New York State: March 2020-December 2022.

Journal of public health management and practice : JPHMP·2024
Same author

Ending Race-Conscious College Admissions and Its Potential Impact on the Infectious Disease Workforce.

Open forum infectious diseases·2024
Same author

From Pandemic to Epidemic: Lessons Learned From COVID-19 Applied to Mpox Outbreak Response, Westchester County, Metropolitan New York.

Journal of public health management and practice : JPHMP·2023
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Omeprazole significantly reduces systemic exposure to nelfinavir and its active metabolite, potentially leading to treatment failure. Coadministration of omeprazole with nelfinavir is not recommended due to reduced drug efficacy.

Area of Science:

  • Pharmacology
  • Drug Interactions
  • Clinical Pharmacology

Background:

  • Nelfinavir is an antiretroviral medication used to treat HIV/AIDS.
  • Omeprazole is a proton pump inhibitor used to reduce stomach acid.
  • Understanding drug interactions is crucial for optimizing patient outcomes.

Purpose of the Study:

  • To evaluate the impact of omeprazole on nelfinavir pharmacokinetics.
  • To assess the safety and tolerability of combined nelfinavir and omeprazole therapy.

Main Methods:

  • An open-label, two-period study involving 20 healthy volunteers.
  • Subjects received nelfinavir alone, followed by nelfinavir with omeprazole.
  • Pharmacokinetic parameters (AUC, Cmax, Cmin) were measured using HPLC-UV.

Related Experiment Videos

Main Results:

  • Omeprazole reduced nelfinavir AUC, Cmax, and Cmin by 36%, 37%, and 39%, respectively.
  • Omeprazole significantly decreased exposure to nelfinavir's active metabolite M8 (AUC, Cmax, Cmin reduced by 92%, 89%, 75%).
  • Both drugs were well-tolerated when administered together.

Conclusions:

  • Reduced systemic exposure to nelfinavir and M8 may compromise virologic control.
  • Coadministration of omeprazole with nelfinavir could lead to drug resistance.
  • Omeprazole should not be used concurrently with nelfinavir.